mCRPC VL

AR-V7: What We Know, What We Think - Christopher Evans

Details
Christopher Evans presents an overview of AR-V7 summarizing the recent literature. (Presented in 6:36) Biography: Christopher Evans, MD is Professor and Chair Department Urology, UC Davis. Dr. Evans' practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy. Dr. Evan...

AR-V7 Testing in Clinical Practice: Not Ready for Prime Time - Tomasz Beer

Details
Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer Access to all Advanced Prostate Cancer Consensus Conference Video Coverage

Treatment of M1 Disease No Local Treatment - Nicolas Mottet

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke

Details
Noel Clarke a Consultant Urologist at Salford Royal Hospital presents in opposition of treating all patients with bone-targeted therapy during his portion of the debate on bone-targeted therapy with zoledronate or denosumab. Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Managing the ‘Start’ and ‘Stop’ of Various Therapies for Treating CRPC Patients - Is Timing Everything?- Karim Fizazi

Details
(Length of lecture - 15 minutes) Dr. Karim Fizazi discusses the 2015 APCCC, and the uncertainty during that period around the optimal timing to initiate treatment to men with CRPC. Two years later, Dr. Fizazi presents clinical trial data that has been gathered since then on different therapy options and shares his opinion on the recommended start and stop intervals for administering these therapie...

When and What hormonal therapy to use for men with castration-sensitive/naive prostate cancer and isolated biochemical recurrence(M0) after radical treatment - Martin Gleave

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

CRPC M0 and M1: Sequencing and Combination Therapy - Take home message - Ian Davis

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer- Karim Fizazi

Details
The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October. Karim Fizazi, MD presents, “Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer” and discusses mechanisms of resistance to ADT with CRPC, mechanisms of CRPC resistance to new drugs and mechanisms of resis...

Management of Chronic Pre-existing or Treatment-emergent Adverse Events of the “other" Systemic Therapies - Michael J. Morris

Details
Michael Morris, Memorial Sloan Kettering Cancer Center, New York, US, focus this discussion on prostate cancer specific aspects of side effects and how we can select the treatments, how to give them in which clinical states, to which patients, at what dose and at what intensity and for what duration. Chemotherapy with docetaxel and cabazitaxel in both mCRPC and mCSPC (non-castrate) is presented al...

Phil Kantoff on AR-V7: Ready for use in daily clinical decision making

Details
Phil Kantoff presented, "AR-V7- ready for use in daily clinical decision making?" a point/counterpoint discussion at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerland. Neal Shore, MD, interview Dr. Kantoff regarding his Pro position on AR-V7 and the risk benefit of certain drugs and tests and the costs involved. Biographies: Dr. Philip Kantoff is the Chairma...